

# Anders KarlÃ©n

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2161193/publications.pdf>

Version: 2024-02-01

27  
papers

1,739  
citations

759233

12  
h-index

552781

26  
g-index

27  
all docs

27  
docs citations

27  
times ranked

2072  
citing authors

#	ARTICLE	IF	CITATIONS
1	Synthesis and <i>In Vitro</i> Biological Evaluation of Quinoliny Pyrimidines Targeting Type II NADH-Dehydrogenase (NDH-2). <i>ACS Infectious Diseases</i> , 2022, 8, 482-498.	3.8	2
2	Bacterial type I signal peptidase inhibitors - Optimized hits from nature. <i>European Journal of Medicinal Chemistry</i> , 2022, 238, 114490.	5.5	4
3	Towards the sustainable discovery and development of new antibiotics. <i>Nature Reviews Chemistry</i> , 2021, 5, 726-749.	30.2	439
4	Antibacterial sulfonimidamide-based oligopeptides as type I signal peptidase inhibitors: Synthesis and biological evaluation. <i>European Journal of Medicinal Chemistry</i> , 2021, 224, 113699.	5.5	10
5	Computational studies of molecular pre-organization through macrocyclization: Conformational distribution analysis of closely related non-macrocyclic and macrocyclic analogs. <i>Bioorganic and Medicinal Chemistry</i> , 2021, 49, 116399.	3.0	3
6	The global preclinical antibacterial pipeline. <i>Nature Reviews Microbiology</i> , 2020, 18, 275-285.	28.6	442
7	Conformational analysis of macrocycles: comparing general and specialized methods. <i>Journal of Computer-Aided Molecular Design</i> , 2020, 34, 231-252.	2.9	19
8	Boronic ester-linked macrocyclic lipopeptides as serine protease inhibitors targeting <i>Escherichia coli</i> type I signal peptidase. <i>European Journal of Medicinal Chemistry</i> , 2018, 157, 1346-1360.	5.5	10
9	Design, synthesis and in vitro biological evaluation of oligopeptides targeting <i>E. coli</i> type I signal peptidase (LepB). <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 897-911.	3.0	10
10	Docking of Macrocycles: Comparing Rigid and Flexible Docking in Glide. <i>Journal of Chemical Information and Modeling</i> , 2017, 57, 190-202.	5.4	49
11	Predicting the Rate of Skin Penetration Using an Aggregated Conformal Prediction Framework. <i>Molecular Pharmaceutics</i> , 2017, 14, 1571-1576.	4.6	11
12	Optimization and Evaluation of 5-Styryl-Oxathiazol-2-one <i>Mycobacterium tuberculosis</i> Proteasome Inhibitors as Potential Antitubercular Agents. <i>ChemistryOpen</i> , 2015, 4, 342-362.	1.9	13
13	Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT <sub>2</sub> Receptor Ligands. <i>ACS Medicinal Chemistry Letters</i> , 2015, 6, 178-182.	2.8	15
14	Novel Peptidomimetic Hepatitis C Virus NS3/4A Protease Inhibitors Spanning the P2-P1 Region. <i>ACS Medicinal Chemistry Letters</i> , 2014, 5, 249-254.	2.8	13
15	Vinylated linear P2 pyrimidinyloxyphenylglycine based inhibitors of the HCV NS3/4A protease and corresponding macrocycles. <i>Bioorganic and Medicinal Chemistry</i> , 2014, 22, 6595-6615.	3.0	4
16	Synthesis, biological evaluation and X-ray crystallographic studies of imidazo[1,2-a]pyridine-based <i>Mycobacterium tuberculosis</i> glutamine synthetase inhibitors. <i>MedChemComm</i> , 2012, 3, 620.	3.4	29
17	Focused hierarchical design of peptide libraries "follow the lead. <i>Journal of Chemometrics</i> , 2007, 21, 486-495.	1.3	8
18	Insight into $\hat{1}^2$ -hairpin stability: a structural and thermodynamic study of diastereomeric $\hat{1}^2$ -hairpin mimetics Electronic supplementary information (ESI) available: temperature and concentration-dependent chemical shifts and melting curves of the investigated molecules in different solvents and details of the X-ray analysis. See <a href="http://www.rsc.org/suppdata/nj/b1/b111241d/">http://www.rsc.org/suppdata/nj/b1/b111241d/</a> . <i>New Journal of Chemistry</i> , 2002, 26, 834-843.	2.8	22

#	ARTICLE	IF	CITATIONS
19	SPR Biosensor Studies of the Direct Interaction between 27 Drugs and a Liposome Surface:Â Correlation with Fraction Absorbed in Humans. Journal of Medicinal Chemistry, 2000, 43, 2083-2086.	6.4	133
20	Inhibitors of the C2-Symmetric HIV-1 Protease:â€ Nonsymmetric Binding of a Symmetric Cyclic Sulfamide with Ketoxime Groups in the P2/P2â€ Side Chains. Journal of Medicinal Chemistry, 1999, 42, 4054-4061.	6.4	53
21	Correlation of Human Jejunal Permeability (in Vivo) of Drugs with Experimentally and Theoretically Derived Parameters. A Multivariate Data Analysis Approach. Journal of Medicinal Chemistry, 1998, 41, 4939-4949.	6.4	420
22	Enantiomer separation of underivatized tocinide and related compounds by CGC using ammonia as carrier gas. Journal of Separation Science, 1996, 8, 151-156.	1.0	4
23	Synthesis of<i>C</i><sub>2</sub>Symmetric Potential Inhibitors of HIV-1 Protease From D-Mannitol. Journal of Carbohydrate Chemistry, 1996, 15, 555-569.	1.1	5
24	Enantiomer separation of underivatized tocinide and related compounds by CGC using ammonia as carrier gas. Journal of Separation Science, 1996, 8, 151-156.	1.0	1
25	Circular dichroism spectroscopy of 2-aminotetralins. Chirality, 1995, 7, 82-89.	2.6	2
26	Stereoselectivity of Drug Receptor Interactions. Drug Information Journal, 1990, 24, 485-496.	0.5	1
27	Conformational analysis of the dopamine-receptor agonist 5-hydroxy-2-(dipropylamino)tetralin and its C(2)-methyl-substituted derivative. Journal of Medicinal Chemistry, 1986, 29, 917-924.	6.4	17